- Current report filing (8-K)
March 03 2010 - 2:04PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM 8-K
CURRENT
REPORT PURSUANT
TO
SECTION 13 OR 15(D) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date of
report (Date of earliest event reported):
March 3,
2010
Interleukin
Genetics, Inc.
(Exact
Name of Registrant as Specified in Its Charter)
Delaware
(State or
Other Jurisdiction of Incorporation)
|
001-32715
|
|
94-3123681
|
|
(Commission
File Number)
|
|
(IRS
Employer Identification No.)
|
|
|
|
|
|
135
Beaver Street Waltham, MA
|
|
02452
|
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
(781)
398-0700
(Registrant’s
Telephone Number, Including Area Code)
(Former
Name or Former Address, if Changed Since Last Report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (
see
General
Instruction A.2. below):
|
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
|
|
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
|
|
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR 240.14d-2(b))
|
|
|
|
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR 240.13e-4(c))
|
On March
3, 2010, Interleukin Genetics, Inc. issued a press release announcing the
presentation of findings from a retrospective clinical study on weight
management conducted in collaboration with Stanford University. The
study results and conclusions were presented on March 3, 2010 by investigators
from Stanford Prevention Research Center at Stanford University School of
Medicine during an oral presentation titled “Genotype Patterns Predict Weight
Loss Success: The Right Diet Does Matter,” at the American Heart Association’s
Joint 50
th
Cardiovascular Disease Epidemiology and Prevention – and – Nutrition, Physical
Activity and Metabolism conference, being held March 2-5 in San Francisco,
CA.
A copy of
the press release is being filed herewith as Exhibit 99.1 and the information
contained therein is incorporated by reference into this Current Report on Form
8-K.
|
ITEM
9.01
|
Financial
Statements and Exhibits.
|
(d)
Exhibits
.
|
Exhibit
Number
|
|
Description of Exhibit
|
|
|
|
|
|
99.1
|
|
Press
release dated March 3,
2010.
|
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
|
|
Interleukin
Genetics, Inc.
|
|
|
|
(Registrant)
|
|
|
|
|
|
Date:
March 3, 2010
|
|
/s/
ELIOT M. LURIER
|
|
|
|
Eliot
M. Lurier
|
|
|
|
Chief
Financial Officer
|
|
|
|
(Signature)
|
Interleukin Genetics (AMEX:ILI)
Historical Stock Chart
From Nov 2024 to Dec 2024
Interleukin Genetics (AMEX:ILI)
Historical Stock Chart
From Dec 2023 to Dec 2024
